Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 7/2016

01-07-2016 | Review Article

Long noncoding RNAs in lung cancer: what we know in 2015

Authors: Y. J. Xu, Y. Du, Y. Fan

Published in: Clinical and Translational Oncology | Issue 7/2016

Login to get access

Abstract

Lung cancer ranks as the first most common cancer and the first leading cause of cancer-related death in China and worldwide. Due to the difficulty in early diagnosis and the onset of cancer metastasis, the 5-year survival rate of lung cancer remains extremely low. Long noncoding RNAs (lncRNAs), which lacking protein-coding ability, have recently emerged as pivotal participants in biological processes, often dysregulated in a range of cancers, including lung cancer. In this review, we highlight the recent findings of lncRNAs in lung cancer pathogenesis. While our understanding of lncRNAs in the onset and progression of lung cancer is still in its infancy, there is no doubt that understanding the activities of lncRNAs will certainly secure strong biomarkers and improve treatment options for lung cancer patients.
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
2.
3.
Thomson CS, Forman D. Cancer survival in England and the influence of early diagnosis: what can we learn from recent EUROCARE results? Br J Cancer. 2009;101:S102–9.CrossRefPubMedPubMedCentral
4.
Kapranov P, Cheng J, Dike S, Nix DA, Duttagupta R, Willingham AT, et al. RNA maps reveal new RNA classes and a possible function for pervasive transcription. Science. 2007;316:1484–8.CrossRefPubMed
5.
6.
Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of posttranscriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet. 2008;9:102–14.CrossRefPubMed
7.
Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature. 2009;458:223–7.CrossRefPubMedPubMedCentral
8.
Pennisi E. Long noncoding RNAs may alter chromosome’s 3D structure. Science. 2013;340:910.
9.
Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009;136(629–41):17.
10.
11.
Mercer TR, Mattick JS. Structure and function of long noncoding RNAs in epigenetic regulation. Nat Struct Mol Biol. 2013;20:300–7.CrossRefPubMed
12.
13.
Brown CJ, Ballabio A, Rupert JL, Lafreniere RG, Grompe M, Tonlorenzi R, et al. A gene from the region of the human X inactivation centre is expressed exclusively from the inactive X chromosome. Nature. 1991;349:38–44.CrossRefPubMed
14.
15.
Chen G, Wang Z, Wang D, Qiu C, Liu M, Chen X, et al. LncRNADisease: a database for long-non-coding RNA-associated diseases. Nucleic Acid Res. 2013;41:D983–6.CrossRefPubMed
16.
17.
Malek E, Jagannathan S, Driscoll JJ. Correlation of long non-coding RNA expression with metastasis, drug resistance and clinical outcome in cancer. Oncotarget. 2014;5:8027–38.CrossRefPubMedPubMedCentral
18.
Godinho M, Meijer D, Setyono-Han B, Dorssers LC, van Agthoven T. Characterization of BCAR4, a novel oncogene causing endocrine resistance in human breast cancer cells. J Cell Physiol. 2011;226:1741–9.CrossRefPubMed
19.
Filella X, Foj L, Mila M, Augé JM, Molina R, Jiménez W. PCA3 in the detection and management of early prostate cancer. Tumour Biol. 2013;34:1337–47.CrossRefPubMed
20.
Xie H, Ma H, Zhou D. Plasma HULC as a promising novel biomarker for the detection of hepatocellular carcinoma. Biomed Res Int. 2013;2013:136106.PubMedPubMedCentral
21.
Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, et al. SOX2 is anamplified lineage-survival oncogene in lung and esophageal squamous cell car-cinomas. Nat Genet. 2009;41:1238–42.CrossRefPubMedPubMedCentral
22.
Hussenet T, Dali S, Exinger J, Monga B, Jost B, Dembelé D, et al. SOX2 is an onco-gene activated by recurrent 3q26.3 amplifications in human lung squamous cellcarcinomas. PLoS One. 2010;5:e8960.CrossRefPubMedPubMedCentral
23.
Kikuchi J, Kinoshita I, Shimizu Y, Kikuchi E, Konishi J, Oizumi S, et al. Distinctive expression of the polycomb groupproteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog2 in nonsmall cell lung cancers and their clinical and clinicopathologic signifi-cance. Cancer. 2010;116:3015–24.CrossRefPubMed
24.
Huqun Ishikawa R, Zhang J, Miyazawa H, Goto Y, Shimizu Y, et al. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall celllung cancer. Cancer. 2012;118:1599–606.CrossRefPubMed
25.
Hou Zhibo, Zhao Wei, Zhou Ji, Shen L, Zhan P, Xu C, et al. A long noncoding RNA Sox2ot regulates lung cancer cell proliferationand is a prognostic indicator of poor survival. Int J Biochem Cell Biol. 2014;53:380–8.CrossRefPubMed
26.
Ji P, Diederichs S, Wang W, Böing S, Metzger R, Schneider PM, et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non–small cell lung cancer. Oncogene. 2003;22:8031–41.CrossRefPubMed
27.
Tripathi V, Ellis JD, Shen Z, Song DY, Pan Q, Watt AT, et al. The nuclearretained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell. 2010;39:925–38.CrossRefPubMedPubMedCentral
28.
Yang L, Lin C, Liu W, Zhang J, Ohgi KA, Grinstein JD, et al. ncRNA- and Pc2 methylation-dependent gene relocation between nuclear structures mediates gene activation programs. Cell. 2011;147:773–88.CrossRefPubMedPubMedCentral
29.
Ji P, Diederichs S, Wang W, Böing S, Metzger R, Schneider PM, et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non–small cell lung cancer. Oncogene. 2003;22:8031–41.CrossRefPubMed
30.
Schmidt LH, Spieker T, Koschmieder S, Schäffers S, Humberg J, Jungen D, et al. The long noncoding MALAT-1 RNA indicates a poor prognosis in non–small cell lung cancer and induces migration and tumor growth. J Thorac Oncol. 2011;6:1984–92.CrossRefPubMed
31.
Tano K, Mizuno R, Okada T, Rakwal R, Shibato J, Masuo Y, et al. MALAT-1 enhances cell motility of lung adenocarcinoma cells by influencing the expression of motility-related genes. FEBS Lett. 2010;584:4575–80.CrossRefPubMed
32.
Gutschner Tony, Hammerle Monika, Eissmann Moritz, Hsu J, Kim Y, Hung G, et al. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res. 2013;73:1180–9.CrossRefPubMed
33.
Shen Liqin, Chen Lei, Wang Yongsheng, Jiang X, Xia H, Zhuang Z. Long noncoding RNA MALAT1 promotes brain metastasis by inducing epithelial–mesenchymal transition in lung cancer. J Neurooncol. 2015;121:101–8.CrossRefPubMed
34.
Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Brugmann SA, et al. Functional demarcation of active and silent chromatin domains in human Hox loci by noncoding RNAs. Cell. 2007;129:1311–23.CrossRefPubMedPubMedCentral
35.
Tsai MC, Manor O, Wan Y, Mosammaparast N, Wang JK, Lan F, et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science. 2010;329:689–93.CrossRefPubMedPubMedCentral
36.
Gupta RA, Shah N, WangKC Kim J, Horlings HM, Wong DJ, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010;464:1071–6.CrossRefPubMedPubMedCentral
37.
Zhao W, An Y, Liang Y, Xie XW. Role of HOTAIR long noncoding RNA in metastatic progression of lung cancer. Eur Rev Med Pharmacol Sci. 2014;18:1930–6.PubMed
38.
Liu XH, Liu ZL, Sun M, Liu J, Wang ZX, De W. The long non-coding RNA HOTAIR indicates a poor prognosis and promotes metastasis in non-small cell lung cancer. BMC Cancer. 2013;13:464.CrossRefPubMedPubMedCentral
39.
Nakagawa T, Endo H, Yokoyama M, Abe J, Tamai K, Tanaka N, et al. Large noncoding RNA HOTAIR enhances aggressive biological behavior and is associated with short disease-free survival in human non-small cell lung cancer. Biochem Biophys Res Commun. 2013;436:319–24.CrossRefPubMed
40.
Liu Z, Sun M, Lu K, Liu J, Zhang M, Wu W, et al. The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregualtion of p21(WAF1/CIP1) expression. PLoS One. 2013;8:e77293.CrossRefPubMedPubMedCentral
41.
Ono H, Motoi N, Nagano H, Miyauchi E, Ushijima M, Matsuura M, et al. Long noncoding RNA HOTAIR is relevant to cellular proliferation, invasiveness, and clinical relapse in small-cell lung cancer. Cancer Med. 2014;3:632–42.CrossRefPubMedPubMedCentral
42.
Thai P, Statt S, Chen CH, Liang E, Campbell C, Wu R. Characterization of a Novel Long Noncoding RNA, SCAL1, Induced by Cigarette Smoke and Elevated in Lung Cancer Cell Lines. Am J Respir Cell Mol Biol. 2013;49:204–11.CrossRefPubMedPubMedCentral
43.
Li P, Li J, Yang R, Zhang F, Wang H, Chu H, et al. Study on expression of lncRNA RGMB-AS1 and repulsive guidance molecule b in non-small cell lung cancer. Diagn Pathol. 2015;10:63.CrossRefPubMedPubMedCentral
44.
Li J, Li P, Zhao W, Yang R, Chen S, Bai Y, et al. Expression of long non-coding RNA DLX6-AS1 in lung adenocarcinoma. Cancer Cell Int. 2015;15:48.CrossRefPubMedPubMedCentral
45.
Zhang J, Zhu N, Chen X. A novel long noncoding RNA LINC01133 is upregulated in lung squamous cell cancer and predicts survival. Tumour Biol. 2015;36:7465–71.CrossRefPubMed
46.
Luo H, Sun Y, Wei G, Luo J, Yang X, Liu W, et al. Functional characterization of long noncoding RNA Lnc_bc060912 in human lung carcinoma cells. Biochemistry. 2015;54(18):2895–902.CrossRefPubMed
47.
Pan LJ, Zhong TF, Tang RX, Li P, Dang YW, Huang SN, et al. Upregulation and clinicopathological significance of long non-coding NEAT1 RNA in NSCLC tissues. Asian Pac J Cancer Prev. 2015;16(7):2851–5.CrossRefPubMed
48.
Wu Y, Liu H, Shi X, Yao Y, Yang W, Song Y. The long non-coding RNA HNF1A-AS1 regulates proliferation and metastasis in lung adenocarcinoma. Oncotarget. 2015;6(11):9160–72.CrossRefPubMedPubMedCentral
49.
Lin L, Gu ZT, Chen WH, Cao KJ. Increased expression of the long non-coding RNA ANRIL promotes lung cancer cell metastasis and correlates with poor prognosis. Diagn Pathol. 2015;10(1):14.CrossRefPubMedPubMedCentral
50.
Hu T, Lu YR. BCYRN1, a c-MYC-activated long non-coding RNA, regulates cell metastasis of non-small-cell lung cancer. Cancer Cell Int. 2015;15:36.CrossRefPubMedPubMedCentral
51.
Yang Q, Xu E, Dai J, Liu B, Han Z, Wu J, et al. A novel long noncoding RNA AK001796 acts as an oncogene and is involved in cell growth inhibition by resveratrol in lung cancer. Toxicol Appl Pharmacol. 2015;285(2):79–88.CrossRefPubMed
52.
Han L, Zhang E-b, Yin D-d, Kong R, Xu TP, Chen WM, et al. Low expression of long noncoding RNA PANDAR predicts a poor prognosis of non-small cell lung cancer and affects cell apoptosis by regulating Bcl-2. Cell Death Dis. 2015;6:e1665.CrossRefPubMedPubMedCentral
53.
Han L, Kong R, Yin DD, Zhang EB, Xu TP, De W, et al. Low expression of long noncoding RNA GAS6-AS1 predicts a poor prognosis in patients with NSCLC. Med Oncol. 2013;30:694.CrossRefPubMed
54.
Sun M, Liu XH, Lu KH, Nie FQ, Xia R, Kong R, et al. EZH2-mediated epigenetic suppression of long noncoding RNA SPRY4-IT1 promotes NSCLC cell proliferation and metastasis by affecting the epithelial–mesenchymal transition. Cell Death Dis. 2014;5:e1298.CrossRefPubMedPubMedCentral
55.
Yang F, Huo XS, Yuan SX, Zhang L, Zhou WP, Wang F, et al. Repression of the long noncoding RNALET by histone deacetylase 3 contributes to hypoxia-mediated metastasis. Mol Cell. 2013;49:1083–96.CrossRefPubMed
56.
Liu J, Wan L, Lu K, Sun M, Pan X, Zhang P, et al. The long noncoding rna meg3 contributes to cisplatin resistance of human lung adenocarcinoma. PLoS One. 2015;10(5):e0114586.CrossRefPubMedPubMedCentral
57.
Xu G, Chen J, Pan Q, Huang K, Pan J, Zhang W, et al. Long noncoding RNA expression profiles of lung adenocarcinoma ascertained by microarray analysis. PLoS One. 2014;9:e104044.CrossRefPubMedPubMedCentral
58.
Wang P, Lu S, Mao H, Bai Y, Ma T, Cheng Z, et al. Identification of biomarkers for the detection of early stage lung adenocarcinoma by microarray profiling of longnoncoding RNAs. Lung Cancer. 2015;88:147–53.CrossRefPubMed
59.
Weber DG, Johnen G, Casjens S, Bryk O, Pesch B, Jöckel KH, et al. Evaluation of long noncoding RNA MALAT1 as a candidate blood-based biomarker for the diagnosis of non-small cell lung cancer. BMC Res Note. 2013;6:518.CrossRef
Metadata
Title
Long noncoding RNAs in lung cancer: what we know in 2015
Authors
Y. J. Xu
Y. Du
Y. Fan
Publication date
01-07-2016
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 7/2016
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-015-1448-y

Other articles of this Issue 7/2016

Clinical and Translational Oncology 7/2016 Go to the issue

Research Article

S-l combined with cisplatin plus concurrent chemoradiotherapy versus cisplatin plus concurrent chemoradiotherapy for Chinese patients with advanced gastric cancer: a multi-centre randomized controlled trial

Research Article

Clinical significance of ECT2 expression in tissue and serum of gastric cancer patients

Research Article

Clinical significance of cellular and acellular mucin pools in rectal carcinoma following preoperative chemoradiotherapy

Research Article

Compliance to radiation therapy of head and neck cancer patients and impact on treatment outcome

Research Article

Landscape of early clinical trials for childhood and adolescence cancer in Spain

Review Article

Targeting the microenvironment of pancreatic cancer: overcoming treatment barriers and improving local immune responses
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits